The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Cantor Upgrades easyJet To Buy From Hold

Tue, 09th Aug 2016 08:33

LONDON (Alliance News) - The following shares received analyst recommendations Tuesday morning and Monday:
----------
FTSE 100
----------
CANTOR FITZGERALD RAISES EASYJET TO 'BUY' ('HOLD') - TARGET 1300 PENCE
----------
TRADERS: MACQUARIE CUTS AVIVA TO 'NEUTRAL' ('OUTPERFORM')
----------
GOLDMAN CUTS AVIVA PRICE TARGET TO 480 (485) PENCE - 'BUY'
----------
BERENBERG RAISES RSA INSURANCE PRICE TARGET TO 501 (448) PENCE - 'HOLD'
----------
CITIGROUP REVISES STANDARD CHARTERED PRICE TARGET TO 750 PENCE - 'BUY'
----------
GOLDMAN RAISES STANDARD CHARTERED PRICE TARGET TO 760 (740) PENCE - 'BUY'
----------
CITIGROUP RAISES HSBC PRICE TARGET TO 600 (515) PENCE - 'BUY'
----------
GOLDMAN RAISES RBS PRICE TARGET TO 240 (235) PENCE - 'BUY'
----------
GOLDMAN CUTS LLOYDS PRICE TARGET TO 53 (55) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES BARCLAYS PRICE TARGET TO 175 (170) PENCE - 'NEUTRAL'
----------
TRADERS: NUMIS CUTS INFORMA TO 'ADD' ('BUY')
----------
RBC RAISES ANTOFAGASTA PRICE TARGET TO 500 (410) PENCE - 'SECTOR PERFORM'
----------
DEUTSCHE BANK RAISES BUNZL PRICE TARGET TO 2520 (2100) PENCE - 'BUY'
----------
JPMORGAN RAISES ASTRAZENECA PRICE TARGET TO 4900 (4800) PENCE - 'NEUTRAL'
----------
CREDIT SUISSE RAISES RELX PRICE TARGET TO 1370 (1210) PENCE - 'NEUTRAL'
----------
FTSE 250
----------
LIBERUM CUTS SERCO GROUP TO 'HOLD' ('BUY') - TARGET 135 (120) PENCE
----------
RBC RAISES INDIVIOR PRICE TARGET TO 325 (185) PENCE - 'SECTOR PERFORM'
----------
GOLDMAN RAISES WILLIAM HILL PRICE TARGET TO 320 (310) PENCE - 'NEUTRAL'
----------
DEUTSCHE BANK CUTS WILLIAM HILL PRICE TARGET TO 390 (420) PENCE - 'BUY'
----------
DEUTSCHE BANK RAISES LADBROKES PRICE TARGET TO 148 (136) PENCE - 'HOLD'
----------
SHORE CAPITAL RAISES OCADO TO 'HOLD' ('SELL')
----------
JPMORGAN CUTS JLT GROUP PRICE TARGET TO 850 (1020) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES MEGGITT PRICE TARGET TO 445 (395) PENCE - 'NEUTRAL'
----------
CITIGROUP RAISES JD WETHERSPOON PRICE TARGET TO 980 (840) PENCE - 'BUY'
----------
CREDIT SUISSE RAISES RENTOKIL INITIAL PT TO 235 (225) PENCE - 'OUTPERFORM'
----------
TRADERS: MACQUARIE RAISES PARAGON GROUP TO 'OUTPERFORM' ('NEUTRAL')
----------
GOLDMAN RAISES VEDANTA RESOURCES PRICE TARGET TO 440 (425) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES METRO BANK PRICE TARGET TO 1630 (1560) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES BBA AVIATION PRICE TARGET TO 285 (186) PENCE - 'NEUTRAL'
----------
MAIN MARKET AND AIM
----------
LIBERUM RAISES BOOHOO PRICE TARGET TO 90 (80) PENCE - 'BUY'
----------
TRADERS: NUMIS RAISES SDL TO 'ADD' ('HOLD')
----------
TRADERS: NUMIS RAISES DEVRO TO 'BUY' ('ADD')
----------
BERENBERG CUTS MOTHERCARE PRICE TARGET TO 100 (130) PENCE - 'SELL'
----------
BERENBERG CUTS CARPETRIGHT PRICE TARGET TO 230 (450) PENCE - 'HOLD'
----------
BERENBERG CUTS TOPPS TILES PRICE TARGET TO 125 (155) PENCE - 'HOLD'
----------
PANMURE RAISES GEMFIELDS RESOURCES PRICE TARGET TO 61 (57) PENCE - 'BUY'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more
11 Sep 2023 21:54

AstraZeneca says Fasenra therapy meets primary endpoint at trial

(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis.

Read more
11 Sep 2023 10:17

UPDATE: AstraZeneca has good results from three cancer drugs in trials

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for lung cancer, while also seeing "strong and durable" tumour responses from its Enhertu antibody drug conjugate.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
11 Sep 2023 06:59

AstraZeneca says Imfinzi and Tagrisso combinations show good results

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for cancer.

Read more
6 Sep 2023 09:36

AstraZeneca working with FDA on Ultomiris risk evaluation changes

(Alliance News) - AstraZeneca PLC on Wednesday said it is working closely with the US Food & Drug Administration regarding a request to changes to improve risk evaluation for Ultomiris.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.